Aethlon medical, inc. announces positive data safety monitoring board review and recommendation to advance to next clinical trial cohort

San diego , july 15, 2025 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a clinical-stage biotechnology company developing the investigational aethlon hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent data safety monitoring board (dsmb) overseeing its ongoing clinical trial aemd-2022-06 has completed its scheduled safety review and recommended advancing to the next patient cohort without modification. the trial, titled "safety, feasibility, and dose-finding study of aethlon hemopurifier in patients with solid tumors who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab", is being conducted to assess the hemopurifier's safety, feasibility, and optimal dosing.
AEMD Ratings Summary
AEMD Quant Ranking